Insider Transaction: CEO Yang Jianshu Purchases Additional Shares in CStone Pharmaceuticals

Stock News

Jun 10

Latest data from the Hong Kong Stock Exchange reveals a significant share purchase by a key company insider.

On June 10th, Executive Director and Chief Executive Officer Yang Jianshu acquired an additional 145,000 shares of CStone Pharmaceuticals-B (HKEX: 02616).

The transaction was executed at an average price of approximately HK$4.2593 per share, amounting to a total investment of about HK$617,600.

Following this purchase, Dr. Yang's total shareholding has increased to roughly 72.4831 million shares, representing a 4.53% stake in the company.

Additional notes indicate that the shares were purchased in the open market using Dr. Yang's personal funds.

The acquired shares correspond to Restricted Share Units and Share Options granted or to be issued under the company's Pre-IPO RSU Scheme, Pre-IPO Share Option Scheme, and Post-IPO Incentive Schemes.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1108230063"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108230063\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108230063?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108230063","market":"nz","top_or_hot":-1,"title":"Insider Transaction: CEO Yang Jianshu Purchases Additional Shares in CStone Pharmaceuticals","media":"Stock News","content":"<p>Latest data from the Hong Kong Stock Exchange reveals a significant share purchase by a key company insider.<br><br>On June 10th, Executive Director and Chief Executive Officer Yang Jianshu acquired an additional 145,000 shares of <b>CStone Pharmaceuticals-B</b> (<b>HKEX: 02616</b>).<br><br>The transaction was executed at an average price of approximately HK$4.2593 per share, amounting to a total investment of about HK$617,600.<br><br>Following this purchase, Dr. Yang's total shareholding has increased to roughly 72.4831 million shares, representing a 4.53% stake in the company.<br><br>Additional notes indicate that the shares were purchased in the open market using Dr. Yang's personal funds.<br><br>The acquired shares correspond to Restricted Share Units and Share Options granted or to be issued under the company's Pre-IPO RSU Scheme, Pre-IPO Share Option Scheme, and Post-IPO Incentive Schemes.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insider Transaction: CEO Yang Jianshu Purchases Additional Shares in CStone Pharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsider Transaction: CEO Yang Jianshu Purchases Additional Shares in CStone Pharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-10 19:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Latest data from the Hong Kong Stock Exchange reveals a significant share purchase by a key company insider.<br><br>On June 10th, Executive Director and Chief Executive Officer Yang Jianshu acquired an additional 145,000 shares of <b>CStone Pharmaceuticals-B</b> (<b>HKEX: 02616</b>).<br><br>The transaction was executed at an average price of approximately HK$4.2593 per share, amounting to a total investment of about HK$617,600.<br><br>Following this purchase, Dr. Yang's total shareholding has increased to roughly 72.4831 million shares, representing a 4.53% stake in the company.<br><br>Additional notes indicate that the shares were purchased in the open market using Dr. Yang's personal funds.<br><br>The acquired shares correspond to Restricted Share Units and Share Options granted or to be issued under the company's Pre-IPO RSU Scheme, Pre-IPO Share Option Scheme, and Post-IPO Incentive Schemes.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1108230063","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108230063","pubTimestamp":1781090495,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Latest data from the Hong Kong Stock Exchange reveals a significant share purchase by a key company insider.On June 10th, Executive Director and Chief Executive Officer Yang Jianshu acquired an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","02616":"基石药业-B","EWH":"香港ETF-iShares MSCI"},"translate_title":"内幕交易：CEO杨建树增持基石药业股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1,"EWH":1},"content_text":"Latest data from the Hong Kong Stock Exchange reveals a significant share purchase by a key company insider.On June 10th, Executive Director and Chief Executive Officer Yang Jianshu acquired an additional 145,000 shares of CStone Pharmaceuticals-B (HKEX: 02616).The transaction was executed at an average price of approximately HK$4.2593 per share, amounting to a total investment of about HK$617,600.Following this purchase, Dr. Yang's total shareholding has increased to roughly 72.4831 million shares, representing a 4.53% stake in the company.Additional notes indicate that the shares were purchased in the open market using Dr. Yang's personal funds.The acquired shares correspond to Restricted Share Units and Share Options granted or to be issued under the company's Pre-IPO RSU Scheme, Pre-IPO Share Option Scheme, and Post-IPO Incentive Schemes.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}